caa a22 4500 606177418 CHVBK 20210128100752.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s00018-015-1887-1 doi (NATIONALLICENCE)springer-10.1007/s00018-015-1887-1 The novel role of miRNAs for tamoxifen resistance in human breast cancer [Elektronische Daten] [Wenwen Zhang, Jing Xu, Yaqin Shi, Qian Sun, Qun Zhang, Xiaoxiang Guan] The selective estrogen receptor modulator tamoxifen is the most commonly used treatment for patients with ER-positive breast cancer. However, tumor cells often develop resistance to tamoxifen therapy, which is a major obstacle limiting the success of breast cancer treatment. miRNAs, as oncogenic or tumor suppressor genes, regulate the expression and function of their related target genes to affect the biological behaviors of cancer cells, including cancer initiation, progression, metastasis, and therapeutic resistance. In detail, many miRNAs associated with breast cancer tamoxifen resistance have been identified, which offer new targets for breast cancer therapy. Here, we review the miRNAs involved in regulation of tamoxifen resistance in human breast cancer and the mechanism of how the modulation of miRNAs may regulate the sensitivity of breast cancer cells to tamoxifen. We also discuss the future prospects of studies about miRNAs in regulation of tamoxifen resistance and miRNA-based therapeutics for tamoxifen resistance breast cancer patients. Springer Basel, 2015 miR-221 nationallicence Endocrine resistance nationallicence Antiestrogen treatment nationallicence Biomarkers nationallicence miRNA-based therapeutics nationallicence MRX34 nationallicence Next generation sequencing nationallicence Zhang Wenwen Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut Xu Jing Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut Shi Yaqin Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut Sun Qian Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut Zhang Qun Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut Guan Xiaoxiang Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut Cellular and Molecular Life Sciences Springer Basel 72/13(2015-07-01), 2575-2584 1420-682X 72:13<2575 2015 72 18 https://doi.org/10.1007/s00018-015-1887-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00018-015-1887-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zhang Wenwen Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut NATIONALLICENCE 700 1- Xu Jing Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut NATIONALLICENCE 700 1- Shi Yaqin Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut NATIONALLICENCE 700 1- Sun Qian Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut NATIONALLICENCE 700 1- Zhang Qun Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut NATIONALLICENCE 700 1- Guan Xiaoxiang Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, 210002, Nanjing, China aut NATIONALLICENCE 773 0- Cellular and Molecular Life Sciences Springer Basel 72/13(2015-07-01), 2575-2584 1420-682X 72:13<2575 2015 72 18